Takkin Lo, MD
Pulmonary Disease · Honolulu, HINPI 1942221742
Payments from drug & device makers
Across 658 payments — averaging $492.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$205K
- AstraZeneca$55K
- Boehringer Ingelheim$48K
- Insmed, Inc.$14K
- Johnson & Johnson$642
- Sanofi$280
- plus $2K from 19 others
What the payments were for
- Consulting fees$11,1703%
- Speaking & faculty fees$263,22581%
- Travel & lodging$35,60911%
- Food & beverage$14,0934%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 298 | $205,258 |
| AstraZeneca | 165 | $54,512 |
| Boehringer Ingelheim | 63 | $48,122 |
| Insmed, Inc. | 24 | $13,708 |
| Johnson & Johnson | 40 | $642 |
| Sanofi | 9 | $280 |
| Regeneron Healthcare Solutions, Inc. | 10 | $271 |
| Medline Industries LP | 2 | $218 |
| AbbVie(2 entities) | 9 | $208 |
| Philips North America LLC | 7 | $168 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $149 |
| Pharming Healthcare, Inc. | 1 | $119 |
| Intercept Pharmaceuticals, Inc. | 5 | $110 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| E.r. Squibb & Sons, L.L.C. | 3 | $72 |
| Genentech USA, Inc. | 3 | $55 |
| Pfizer | 2 | $48 |
| Dova Pharmaceuticals | 2 | $43 |
| Mirum Pharmaceuticals, Inc. | 1 | $27 |
| Irhythm Technologies, Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Orphalan Inc | 1 | $21 |
| Merck | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Dynavax Technologies Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$120,991
- OFEV$44,204
- TEZSPIRE$36,737
- TRELEGY ELLIPTA$29,571
- Arikayce$11,647
- FASENRA$10,087
- AIRSUPRA$4,944
- ANORO ELLIPTA$2,400
- MEDLINE INDUSTRIES, INC.$138
- JOENJA$119
How this compares
$324,215 in reported general payments places this provider in the 95th percentile of 44 pulmonary disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 716 | $547,836 |
| OfevNintedanib Esylate | 18 | $212,889 |
| TezspireTezepelumab-Ekko | 30 | $120,057 |
| Spiriva RespimatTiotropium Bromide | 100 | $68,931 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 98 | $67,046 |
| Breo ElliptaFluticasone/Vilanterol | 82 | $35,959 |
| Arnuity ElliptaFluticasone Furoate | 63 | $27,296 |
| EliquisApixaban | 39 | $24,307 |
| XareltoRivaroxaban | 23 | $24,080 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $21,071 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $18,869 |
| Incruse ElliptaUmeclidinium Bromide | 29 | $15,205 |
| SymbicortBudesonide/Formoterol Fumarate | 52 | $14,782 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $12,790 |
| Wixela InhubFluticasone Propion/Salmeterol | 87 | $10,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $205,258 | $655,257953 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat | $48,122 | $300,689145 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $54,512 | $201,885180 claims |
| PfizerEliquis | $48 | $24,30739 claims |
| Johnson & JohnsonXarelto | $642 | $24,08023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Honolulu
- Bradley TokeshiHonolulu$107K
- Christopher FiackHonolulu$56K
- Ernie YimHonolulu$20K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- Ronson SatoHonolulu$14K
- Alvin FuruikeHonolulu$10K
- Brent MatsudaHonolulu$10K
- James YangHonolulu$8K
- Katsufumi NishidaHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.